JP2013536195A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536195A5
JP2013536195A5 JP2013524318A JP2013524318A JP2013536195A5 JP 2013536195 A5 JP2013536195 A5 JP 2013536195A5 JP 2013524318 A JP2013524318 A JP 2013524318A JP 2013524318 A JP2013524318 A JP 2013524318A JP 2013536195 A5 JP2013536195 A5 JP 2013536195A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
chelate complex
pharmaceutical composition
complex comprises
chelate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536195A (ja
JP5775581B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2011/000956 external-priority patent/WO2012021985A1/en
Publication of JP2013536195A publication Critical patent/JP2013536195A/ja
Publication of JP2013536195A5 publication Critical patent/JP2013536195A5/ja
Application granted granted Critical
Publication of JP5775581B2 publication Critical patent/JP5775581B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013524318A 2010-08-20 2011-08-18 オリゴヌクレオチドキレート錯体 Active JP5775581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
US61/375,257 2010-08-20
PCT/CA2011/000956 WO2012021985A1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Publications (3)

Publication Number Publication Date
JP2013536195A JP2013536195A (ja) 2013-09-19
JP2013536195A5 true JP2013536195A5 (cg-RX-API-DMAC10.html) 2014-04-10
JP5775581B2 JP5775581B2 (ja) 2015-09-09

Family

ID=45594559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524318A Active JP5775581B2 (ja) 2010-08-20 2011-08-18 オリゴヌクレオチドキレート錯体

Country Status (35)

Country Link
US (2) US8513211B2 (cg-RX-API-DMAC10.html)
EP (1) EP2605794B1 (cg-RX-API-DMAC10.html)
JP (1) JP5775581B2 (cg-RX-API-DMAC10.html)
KR (3) KR20150039873A (cg-RX-API-DMAC10.html)
CN (2) CN103768086B (cg-RX-API-DMAC10.html)
AU (1) AU2011291401B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013003875B1 (cg-RX-API-DMAC10.html)
CA (2) CA2855690C (cg-RX-API-DMAC10.html)
CL (1) CL2013000445A1 (cg-RX-API-DMAC10.html)
CO (1) CO6670525A2 (cg-RX-API-DMAC10.html)
CR (1) CR20130069A (cg-RX-API-DMAC10.html)
CU (1) CU20130022A7 (cg-RX-API-DMAC10.html)
CY (1) CY1118207T1 (cg-RX-API-DMAC10.html)
DK (1) DK2605794T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2013000041A (cg-RX-API-DMAC10.html)
EA (1) EA026660B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP13012449A (cg-RX-API-DMAC10.html)
ES (1) ES2598556T3 (cg-RX-API-DMAC10.html)
GT (1) GT201300040A (cg-RX-API-DMAC10.html)
HR (1) HRP20161333T1 (cg-RX-API-DMAC10.html)
HU (1) HUE029521T2 (cg-RX-API-DMAC10.html)
IL (1) IL224237A (cg-RX-API-DMAC10.html)
LT (1) LT2605794T (cg-RX-API-DMAC10.html)
MX (1) MX340294B (cg-RX-API-DMAC10.html)
MY (1) MY160961A (cg-RX-API-DMAC10.html)
NZ (1) NZ606364A (cg-RX-API-DMAC10.html)
PH (1) PH12013500192B1 (cg-RX-API-DMAC10.html)
PL (1) PL2605794T3 (cg-RX-API-DMAC10.html)
PT (1) PT2605794T (cg-RX-API-DMAC10.html)
RS (1) RS55245B1 (cg-RX-API-DMAC10.html)
SG (1) SG187165A1 (cg-RX-API-DMAC10.html)
SI (1) SI2605794T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201600370B (cg-RX-API-DMAC10.html)
WO (1) WO2012021985A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201300497B (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー.フェー. Dnaリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス, インコーポレイテッド 遺伝子発現と疼痛
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
PT2841578T (pt) 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
RU2668136C2 (ru) * 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
HUE054875T2 (hu) * 2012-05-18 2021-10-28 Replicor Inc Oligonukleotid kelátkomplex-polipeptid készítmények és eljárások
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
CN104603271B (zh) * 2012-07-03 2019-07-19 马林生物科技有限公司 用于治疗肌肉萎缩症患者的寡核苷酸
CN104837501B (zh) 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
KR20170029577A (ko) 2014-07-10 2017-03-15 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
JP2018513127A (ja) 2015-04-23 2018-05-24 ジェロン・コーポレーションGeron Corporation 多価カチオン塩組成物を用いたポリヌクレオチド調製方法
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20200147124A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
JP2024521897A (ja) * 2021-06-02 2024-06-04 アタランタ セラピューティクス,インコーポレーテッド 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法
CN117616121A (zh) 2021-07-09 2024-02-27 葛兰素史密斯克莱知识产权(第3号)有限公司 寡核苷酸用于具有肾脏损伤的个体的用途
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
WO2005023829A1 (ja) * 2003-09-02 2005-03-17 Japan Science And Technology Agency 金属錯体型核酸
WO2005026188A1 (ja) * 2003-09-08 2005-03-24 Japan Science And Technology Agency 金属錯体型核酸
WO2007005626A1 (en) * 2005-07-01 2007-01-11 Bioveris Corporation Compositions and methods for detecting, amplifying, and/or isolating nucleic acids
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Similar Documents

Publication Publication Date Title
JP2019194212A5 (cg-RX-API-DMAC10.html)
PH12013500192B1 (en) Oligonucleotide chelate complexes
Živec et al. Different types of copper complexes with the quinolone antimicrobial drugs ofloxacin and norfloxacin: Structure, DNA-and albumin-binding
IL316808A (en) Modified double-stranded RNA materials and their uses
JP2016512230A5 (cg-RX-API-DMAC10.html)
JP2013542247A5 (cg-RX-API-DMAC10.html)
JP2013507415A5 (cg-RX-API-DMAC10.html)
JP2014521735A5 (cg-RX-API-DMAC10.html)
JP2013532729A5 (cg-RX-API-DMAC10.html)
US9370535B2 (en) Method for treatment of advanced solid tumors
JP2014510729A5 (cg-RX-API-DMAC10.html)
MX2010004089A (es) Compuestos metalicos mezclados para el tratamiento de hiperfosfatemia.
SI2268292T1 (en) Method and compositions for the treatment of cancer
HRP20200822T1 (hr) Pripravci i postupci za inhibiciju ekspresije gena alas1
JP2012511510A5 (cg-RX-API-DMAC10.html)
EP2699233A1 (en) A method for the treatment of a solid tumour
CA2672839A1 (en) Treatment of lung cancer with s-farnesylthiosalicylic acid and analogs thereof
JP2014530181A5 (cg-RX-API-DMAC10.html)
Douillard et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
JP2013544892A5 (cg-RX-API-DMAC10.html)
JP2012504584A5 (cg-RX-API-DMAC10.html)
WO2011031890A4 (en) Cancer stem cell-targeted and drug resistant cancer therapy
JP2011507839A5 (cg-RX-API-DMAC10.html)
JP2012526099A5 (cg-RX-API-DMAC10.html)
WO2012040164A3 (en) Tlr5 ligands, therapeutic methods, and compositions related thereto